BackgroundTubal sterilization is the method of family planning most commonly used. The existence of the post-tubal-ligation syndrome of menstrual abnormalities has been the subject of debate for decades.MethodsIn a cross-sectional study, 112 women with the history of Pomeroy type of tubal ligation achieved by minilaparatomy as the case group and 288 women with no previous tubal ligation as the control group were assessed for menstrual abnormalities.ResultsMenstrual abnormalities were not significantly different between the case and control groups (p = 0.824). The abnormal uterine bleeding frequency differences in two different age groups (30–39 and 40–45 years old) were statistically significant (p = 0.0176).ConclusionTubal sterilization does not cause menstrual irregularities.
Background/Aims: The role of human papillomavirus (HPV) in the etiology of cervical cancer is now well established. This investigation was designed to study the prevalence of the four most common high-risk HPVs in the archival tissues with precancerous and cancerous lesions from patients from northwestern Iran. Methods: 133 formalin-fixed paraffin-embedded tissue specimens were tested for HPV DNA by using GP5+/6+-based general PCR and two type-specific PCRs. Results: In total, 84 (64%) out of 131 amplifiable samples were positive for HPV DNA. The most prevalent oncogenic HPV was type 16 (67.6%) followed by types 31 (22.8%), 18 (7.6%) and 33 (1%). Multiple HPV infections were present in 20 (15.3%) of the 131 samples. Notably, of these 20 cases with multiple infections, 15 were from patients with invasive cervical cancer. Conclusions: The multiplicity of HPV genotypes was noted in invasive cervical carcinoma samples, along with rather different circulating HPV types in the study population. Hence, relevant HPV typing information in cervical carcinoma is very important for planning more efficient screening programs and for further HPV vaccine design.
Introduction Of all the female malignancies, most clinical discussions focus on ovarian cancer. It has the highest case fatality ratio and it is the fifth most common cause of malignancyrelated death among women. The cancer is associated with low parity and infertility. Early menarche and late menopause increase the risk of ovarian cancer. Ovarian cancers include epithelial and non-epithelial tumors. More than 80% of epithelial ovarian cancers are seen in postmenopausal women. The peak incidence of epithelial ovarian cancer is between 55 to 60 years of age. Data show that feature of CA125 increases if the test is performed by transvaginal ultrasound. Its symptoms include complex pelvic mass such as solid pattern, heterogeneous component with irregular thick septum, bilateral masses, and size of lesions exceeding 8 cm. The effective factors in the prognosis of ovarian cancer are divided into the 3 categories of pathological, biological and clinical factors. The pathological factors include the structure and degree of lesion. The biological factors include ploidy and proto-oncogenes such as HER-2neu. The clinical factors include the stage of tumor, the extent of residual disease after primary surgery, volume of ascites, age of the patient, and functional status of patient. Ovarian cancer treatment includes primary cytoreductive and then chemotherapy (1). Chemotherapy may be associated with the complications such as nausea and vomiting, bone marrow depression, peripheral neuropathy, weight loss, hemolytic anemia, and transient cortical blindness (2). Ginger is a plant with anti-carcinogenic and antioxidative effects and modern studies have shown other treatment effects such as the ability to inhibit formation of inflammatory products, direct anti-inflammatory effects, and anti-tumoral effects. It has been proved that the active ingredient in ginger can kill cancer cells due to apoptosis and autophagocytosis. This has also been emphasized in ovarian cancers (2). On the other hand, although chemotherapy drugs suppress inflammatory markers, cancer cells may show resistance to them. It has been proved that ginger can
Objective: The aim of this study was to evaluate fertility-sparing therapy in young patients with endometrial carcinoma. Methodology: This prospective study was carried out on 8 patients with clinical and radio-graphic stage IA, well differentiated endometrioid adenocarcinoma of the endometrium in Alzahra hospital, Tabriz, Iran. Treatment comprised high-dose megestrol acetate. Dilatation and curettage was repeated every three months. Results: The mean age of the patients was 30 (SD,3.21) years (range 24-35). Of the 8 patients, 7 (87.5%) achieved complete response. The mean time to response was 6.5 months (range 3-9). Of the complete responders, 3 of 7(42.8%) had recurrence; one patient underwent immediate hysterectomy, and 2 were successfully treated with second-line therapy and both subsequently conceived. Conception occurred in 3 of 7 patients (42.8%), in two more than once, However successful pregnancy occurred only in two patients. One patient developed Concomitant ovarian adenocarcinoma. Conclusions: High dose progestin therapy can be an effective fertility-sparing treatment in young patients with well differentiated stage IA endometrial endometrioid cancer confined to endometrium. However, close follow up is required because of risks of conservative treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.